Introduction
============

CD163 is a cortisol-regulated monocyte and macrophage-speciﬁc surface glycoprotein and the extracellular portion of CD163 circulates in blood as a soluble protein (sCD163) ([@bib1]).

sCD163 is highly elevated in acute infections including bacteremia and sepsis ([@bib2], [@bib3], [@bib4]) and in inflammatory liver diseases ([@bib5], [@bib6], [@bib7], [@bib8]).

*In vitro*, lipopolysaccharide (LPS, endotoxin) induces ectodomain shedding of sCD163 by TLR-4 stimulation of the metalloproteinase TACE ([@bib9]). LPS is a constituent of the outer membrane of the cell wall of gram-negative bacteria. LPS acts as a mediator of both acute and chronic inflammation ([@bib10], [@bib11], [@bib12], [@bib13]) and is an important mediator of gram-negative sepsis ([@bib14]).

*In vivo*, high doses of LPS (from 2 ng/kg to 4 ng/kg) are used as a human model of the initial phase of sepsis ([@bib15]), and in these settings, LPS administration increases plasma CD163 within minutes to the high levels seen in sepsis ([@bib9], [@bib16]).

Small, but significant, increases in sCD163 are seen in conditions of low-grade inflammation, such as obesity, insulin resistance and type 2 diabetes mellitus (T2D) ([@bib17], [@bib18], [@bib19], [@bib20]), but it is not known if these changes are directly linked to low-grade endotoxinemia or they are indirect, since LPS acts through a number of cytokines and also activates the hypothalamo-pituitary axis (HPA) and stimulates the release of stress hormones (e.g. cortisol) into the blood ([@bib21], [@bib22], [@bib23]).

Since CD163 is strongly expressed in tissues such as liver, spleen and lungs, and only moderately expressed on monocytes, it has been suggested that the major fraction of the shedded sCD163 originates from the tissues, but this has not been thoroughly investigated in clinical experiments.

In two placebo-controlled human trials we, therefore, aimed (1) to compare the effects of LPS on levels of sCD163 in hypopituitary patients (HP) (in the absence of pituitary stress hormone responses) and control subjects (CTR) by infusing LPS systemically (intravenously) ('the systemic study') and (2) to investigate the local effect of LPS on levels of sCD163 in healthy volunteers by infusing LPS into the femoral artery with collection of blood from the femoral vein ('the leg study').

Methods
=======

The systemic study
------------------

The study had a randomized placebo-controlled design with two different study days. We studied eight HP and eight matched control subjects (CTR) on two occasions separated by a minimum of1 month: (1) during continuous isotonic saline infusion (placebo day) and (2) during continuous *Escherichia coli* endotoxin infusion of 0.06 ng/kg/h (LPS day) intravenously for 6 h, as previously described ([@bib24]). Blood was sampled at 0, 60, 220 and 340 min for sCD163 analysis.

### HP

As previously described ([@bib24]), seven HP underwent operation for nonfunctioning pituitary adenoma and one patient for craniopharyngioma and all patients developed panhypopituitary insufficiency afterward. All patients received substitution therapy with hydrocortisone, thyroxine, testosterone and growth hormone. In addition, one patient received desmopressin therapy. Average treatment length was 9 years. All HP were healthy (beside their pituitary deficiencies) and did not receive other medications that may influence the results.

HP did not take growth hormone and desmopressin medication the last day before the study and hydrocortisone was discontinued on the study day. HP received i.v. hydrocortisone 80 mg (13 mg/h) continuously during the experiment (*t* = 0--360 min) to avoid acute cortisol deficiency. This high dosage was based on pilot experiments with lesser doses which induced signs of cortisol deficiency (low blood pressure, nausea, vomiting).

The leg study
-------------

As previously described ([@bib25]), catheters were inserted into the femoral artery and vein of both legs in eight healthy male volunteers, and arterial catheters were used for infusion of either LPS (0.025 ng/kg/h) or placebo (saline), respectively in each leg, in a single-blinded randomized manner. Blood samples were taken from both venous catheters at 0, 60, 170 and 350 min for sCD163 analysis.

Both studies were approved by the Central Denmark Region Ethics Committee (M-2010-0076), in accordance with the Declaration of Helsinki. The study protocol was registered at [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (Nbib1452958).

Consent has been obtained from each patient or subject after full explanation of the purpose and nature of all procedures used.

### ELISA for sCD163

We determined serum concentrations of sCD163 in duplicate samples that had been stored for up to 3 years at −80°C by use of an in-house sandwich ELISA on a BEP-2000 ELISA-analyzer (Dade Behring, Germany) ([@bib22]). In each run, we co-analyzed control samples and serum standards with concentrations traceable to purified CD163. The inter-assay imprecision was \<5% CV. The limit of detection was 6.25 µg/L. Soluble CD163 is robust to thawing and prolonged freezing ([@bib22]).

### Hyperinsulinemic--euglycemic clamp

As previously described ([@bib24]), the study consisted of a 240-min basal period, followed by a 120-min hyperinsulinemic--euglycemic clamp period in the systemic study, and 180-min basal period and 180-min clamp period in the leg study ([@bib25]).

Infusion rates of insulin during the clamp period (Insulin Actrapid; Novo-Nordisk) were 1.0 mU/kg/min i.v. Systemic plasma glucose was clamped at 5 mmol/L by a variable infusion of 20% glucose and arterial plasma glucose concentrations were measured at least every ten minutes (Beckman Instruments, Palo Alto, CA, USA).

### Statistics

Data are presented as mean ± [s.e.m.]{.smallcaps} Statistical analysis was performed using paired *t*-tests comparing the effect of LPS vs placebo, unless otherwise stated. In the absence of normal distribution, *P* values were calculated by Wilcoxon signed-rank test. Normal distribution was assessed by inspection of QQ-plots.

Results
=======

Effects of continuous systemic LPS infusion on serum concentrations of sCD163 (*The systemic study*)
----------------------------------------------------------------------------------------------------

Continuous intravenous LPS infusion in healthy controls resulted in an increase in sCD163 at 220 min (1.92 ± 0.46 mg/L LPS day vs 1.65 ± 0.51 mg/L placebo day, *P* = 0.005), and a further increase at 340 min (2.19 ± 0.56 mg/L LPS day vs 1.66 ± 0.42 mg/L placebo day, *P* = 0.006) ([Fig. 1A](#fig1){ref-type="fig"}). A similar increase was observed in HP at 220 min (1.83 ± 0.45 mg/L LPS day vs 1.59 ± 0.53 mg/L placebo day, *P* = 0.021) and at 340 min (2.03 ± 0.44 mg/L LPS day vs 1.52 ± 0.53 mg/L placebo day, *P* \< 0.001) ([Fig. 1B](#fig1){ref-type="fig"}).Figure 1(A) sCD163 serum concentrations (mg/L) during continuous venous LPS/placebo (saline) infusion in eight healthy men. (B) sCD163 serum concentrations (mg/L) during continuous venous LPS/placebo (saline) infusion in eight hypopituitary men. Black bars = LPS infusion day, white bars = placebo infusion day. \**P* value \<0.05 LPS vs placebo, ^\#^*P* value \<0.05 compared to 0 min. *P* values were calculated by paired *t*-test and signed-rank test (where appropriate).

Effects of continuous local LPS infusion on serum concentrations of sCD163 (*The leg study*)
--------------------------------------------------------------------------------------------

In contrast to the systemic LPS infusion, concentrations of sCD163 in the femoral vein were not significantly increased by local LPS infusion ([Fig. 2](#fig2){ref-type="fig"}).Figure 2sCD163 serum concentrations during continuous intra-arterial LPS/placebo (saline) infusion in human leg. Black bars = LPS leg, white bars = placebo leg. \**P* value \<0.05 LPS vs placebo, ^\#^*P* value \<0.05 compared to 0 min. *P* values were calculated by paired *t*-test and signed-rank test (where appropriate).

Cortisol levels
---------------

As previously described ([@bib24]), overall TW ANOVA for repeated measurements revealed a main LPS effect to increase cortisol levels (*P* \< 0.001) in CTR and the difference was significant both during the first 240 min ('basal period'): 88 ± 9 ng/mL (placebo) vs 138 ± 17 ng/mL (LPS), *P* = 0.017, and after 360 min (insulin stimulation -- 'clamp') of the experiment: 94 ± 11 ng/mL (placebo) vs 211 ± 20 ng/mL, *P* = 0.002.

Cortisol levels in HP remained unaltered both during the first 240 min: 315 ± 35 ng/mL (placebo) vs 315 ± 31 ng/mL (LPS), *P* = 0.902, and after 360 min: 342 ± 37 ng/mL (placebo) vs 339 ± 35 ng/mL (LPS), *P* = 0.774. Main LPS effect to increase cortisol levels (TW ANOVA for repeated measurements) was also unaltered (*P* = 0.858). Cortisol levels were not measured in the leg study.

Glucose levels
--------------

### The systemic study

As previously described ([@bib24]), systemic plasma glucose was approximately at 5 mmol/L both in CTR and HP, and there was no difference between placebo and LPS days.

In CTR, glucose levels were 5.4 ± 0.1 mmol/L (placebo) vs 5.1 ± 0.1 mmol/L (LPS), *P* = 0.383, during the first 240 min, and after 360 min glucose levels were 4.9 ± 0.1 mmol/L (placebo) vs 4.9 ± 0.1 mmol/L (LPS), *P* = 0.872.

In HP glucose levels were 5.7 ± 0.3 mmol/L (placebo) vs 5.5 ± 0.1 mmol/L (LPS), *P* = 0.459, during the first 240 min, and after 360 min, glucose levels were 5.0 ± 0.1 mmol/L (placebo) vs 5.1 ± 0.1 mmol/L (LPS), *P* = 0.347.

### The leg study

As previously described ([@bib25]), overall TW ANOVA for repeated measurements revealed a main LPS effect to decrease glucose differences (*P* = 0.015) in the leg, although glucose arterio-venous differences during the clamp only reached borderline significance (*P* = 0.068) when tested separately.

Discussion
==========

This study answers an important question in relation to the low-grade inflammation biomarker sCD163. We show in a randomized controlled design that low-dose systemic LPS directly and within hours increases sCD163 in plasma independently of a cortisol response. sCD163 is regarded as an important biomarker of low-grade inflammation which reflects insulin resistance and is related to increased diabetes risk. In our systemic study we mimicked low-grade inflammation by infusion of low-dose LPS and found a 25% consistent increase in sCD163, which is equivalent to the increase observed in obesity and diabetes. This increase did not depend on activation of the HPA axis, indicating a direct effect of LPS on monocytes and macrophages as seen in the *in vitro* and sepsis situations. *In vitro*, the cellular CD163 expression is upregulated by glucocorticoid after 12--24 h, and it is a possibility that our relatively short observation period failed to detect a more delayed cortisol effect. The HP patients in the study received 80 mg Solu-cortef over the 6 h -- the same dosage during the placebo days and during the LPS days, however, with no effect on sCD163 on the placebo days. Taken together, our data demonstrate that the changes in sCD163 seen in low-grade inflammatory conditions may be directly mediated by low levels of LPS. We cannot, however, exclude that over time, regulatory mechanisms such as HPA activation may contribute to further increased CD163 expression and shedding.

The leg study shows no increase in venous sCD163 neither in the infused nor noninfused leg. Since there is no increase in sCD163 in the noninfused leg, this may indicate that only a minor fraction of the locally injected LPS reaches the systemic circulation. The lack of increase in the LPS-injected leg suggests that monocytes and tissue macrophages in the leg do not substantially contribute to the increase in sCD163 seen after systemic administration.

The strengths of our study include the randomized and placebo-controlled design and the inclusion of systemic vs local low-grade endotoxinemia. Moreover, we investigated the cortisol-independent effects of low-grade endotoxinemia on sCD163.

The study originates from a randomized study comparing saline infusion with LPS-induced inflammation's effect on human metabolism during amino acids, fat and glucose tracers (isotopes) and insulin stimulation in the last part of the experiments. We do not, however, have any reason to believe that either tracers or insulin have affected sCD163 response.
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